Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 16/20 | 0.47 |
| ▸ | S1PR3 | Q99500 | 12/20 | 0.47 |
| ▸ | CACNA1G | O43497 | 4/20 | 0.37 |
| ▸ | CACNA1H | O95180 | 4/20 | 0.37 |
| ▸ | CACNA1I | Q9P0X4 | 4/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1859679 | 0.88 | S1PR1 (0.42) | S1PR1S1PR3CACNA1GCACNA1HCACNA1I | |
| SCHEMBL1855197 | 0.88 | S1PR1 (0.41) | S1PR1S1PR3CACNA1GCACNA1HCACNA1I | |
| SCHEMBL1857312 | 0.88 | S1PR1 (0.47) | S1PR1S1PR3CACNA1GCACNA1HCACNA1I | |
| SCHEMBL12663226 | 0.87 | S1PR1 (0.47) | S1PR1S1PR3CACNA1GCACNA1HCACNA1I | |
| SCHEMBL1862376 | 0.85 | S1PR1 (0.47) | S1PR1S1PR3 | |
| SCHEMBL1856213 | 0.84 | S1PR1 (0.50) | S1PR1S1PR3CACNA1GCACNA1HCACNA1I | |
| SCHEMBL2747390 | 0.84 | S1PR1 (0.48) | S1PR1S1PR3 | |
| SCHEMBL1858060 | 0.80 | S1PR1 (0.55) | S1PR1S1PR3CACNA1GCACNA1HCACNA1I | |
| SCHEMBL1863258 | 0.79 | S1PR1 (0.38) | S1PR1S1PR3CACNA1GCACNA1HCACNA1I | |
| SCHEMBL1867640 | 0.77 | S1PR1 (0.42) | S1PR1S1PR3CACNA1GCACNA1HCACNA1I |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8697732-B2 | Pyridine derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2014-04-15 | — | — | US | disclosed |
| US-20120195930-A1 | NOVEL PYRIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-08-02 | — | — | US | disclosed |
| US-8178562-B2 | Pyridine derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2012-05-15 | — | — | US | disclosed |
| US-8039644-B2 | Hydrogenated benzo (C) thiophene derivatives as immunomodulators | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-10-18 | — | — | US | disclosed |
| US-8039644-B2 | Hydrogenated benzo (C) thiophene derivatives as immunomodulators | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-10-18 | — | — | US | disclosed |
| US-8039644-B2 | Hydrogenated benzo (C) thiophene derivatives as immunomodulators | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-10-18 | — | — | US | disclosed |
| US-7981924-B2 | Thiophene derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-07-19 | — | — | US | disclosed |
| US-7981924-B2 | Thiophene derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-07-19 | — | — | US | disclosed |
| US-7981924-B2 | Thiophene derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-07-19 | — | — | US | disclosed |
| EP-1863787-B1 | HYDOGRENATED BENZO[C]THIOPHENE DERIVATIVES AS IMMUNOMODULATORS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-05-25 | — | — | EP | disclosed |
| US-20080300294-A1 | Novel Thiophene Derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-12-04 | — | — | US | disclosed |
| EP-1979345-A2 | NOVEL PYRIDINE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2008-10-15 | — | — | EP | disclosed |
| EP-1954688-A1 | NOVEL THIOPHENE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2008-08-13 | — | — | EP | disclosed |
| US-20080176926-A1 | G protein-coupled receptor S1P1/EDG1 agonists; 3-(4-hydroxy-3,5-dimethyl-phenyl)-1-(3,5,5-trimethyl-4,5,6,7-tetrahydro-benzo[c]thiophen-1-yl)-propan-1-one; transplant rejection, graft-versus-host diseases, autoimmune syndromes; side effects reduction; immunosuppressive agents; Crohn's disease | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-07-24 | — | — | US | disclosed |
| US-20080176926-A1 | G protein-coupled receptor S1P1/EDG1 agonists; 3-(4-hydroxy-3,5-dimethyl-phenyl)-1-(3,5,5-trimethyl-4,5,6,7-tetrahydro-benzo[c]thiophen-1-yl)-propan-1-one; transplant rejection, graft-versus-host diseases, autoimmune syndromes; side effects reduction; immunosuppressive agents; Crohn's disease | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-07-24 | — | — | US | disclosed |
| EP-1863787-A1 | HYDOGRENATED BENZO[C]THIOPHENE DERIVATIVES AS IMMUNOMODULATORS | Actelion Pharmaceuticals Ltd. (CH) | 2007-12-12 | — | — | EP | disclosed |
| WO-2007086001-A2 | NOVEL PYRIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2007-08-02 | — | — | WO | disclosed |
| WO-2007060626-A1 | NOVEL THIOPHENE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007060626-A1 | NOVEL THIOPHENE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2007-05-31 | — | — | WO | disclosed |
| WO-2006100631-A1 | HYDROGENATED BENZO (C) THIOPHENE DERIVATIVES AS IMMUNOMODULATORS | ACTELION PHARMACEUTICALS LTD (CH) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300294-A1 | Novel Thiophene Derivatives | TPMT, TSLP, NFATC1 | S1PR1 1258/4885S1PR3 1088/4885CACNA1G 3634/4885 |
| US-20120195930-A1 | NOVEL PYRIDINE DERIVATIVES | NFATC1, TPMT, CD47 | S1PR1 1245/4885S1PR3 1086/4885CACNA1G 3195/4885 |
| US-20080176926-A1 | G protein-coupled receptor S1P1/EDG1 agonists; 3-(4-hydroxy-3,5-dimethyl-phenyl)-1-(3,5,5-trimethyl-4,5,6,7-tetrahydro-benzo[c]thiophen-1-yl)-propan-1-one; transplant rejection, graft-versus-host diseases, autoimmune syndromes; side effects reduction; immunosuppressive agents; Crohn's disease | S1PR1, S1PR3, S1PR5 | S1PR1 1/4885S1PR3 2/4885CACNA1G 483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.